CPAP APAP denied as experimental or investigational by Humana?

Humana's specific coverage criteria for cpap apap are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issues an Experimental Denial for CPAP/APAP

A denial of CPAP or APAP therapy on "experimental or investigational" grounds is unusual, because standard PAP therapy for obstructive sleep apnea has decades of clinical use and is recognized as the established first-line intervention by major sleep-medicine organizations. When Humana applies this label to a PAP-related claim, it is almost always because (a) a specific device feature or technology (e.g., an adaptive servo-ventilation mode, an embedded telemonitoring feature, or a newly cleared device variant) was deemed investigational, (b) the indication being treated is an off-label or less common use of PAP therapy, or (c) the denial was issued in error by applying the wrong policy category.

Because standard CPAP/APAP for diagnosed obstructive sleep apnea is not experimental, this type of denial is among the most appealable you can receive. External reviewers — independent IROs — are well-positioned to overturn it when you provide evidence of established clinical acceptance.

## Federal Appeal Rights

• ERISA §503 (self-funded employer plans): full-and-fair internal review with written reasons.
• ACA §2719 (fully insured plans): independent external review by an accredited IRO. Experimental/investigational denials are explicitly covered by the external-review process under the ACA.
• External-review window: approximately four months from the internal denial — verify the exact deadline on your denial letter.
• Expedited review: available if delay would seriously jeopardize health.

## Concrete Appeal Process

1. Request the full denial notice and identify the exact policy language Humana used to classify the therapy as experimental. 2. Request Humana's experimental/investigational technology assessment policy in writing. 3. Identify whether the denial targets the device itself, a specific feature, or the indication being treated. 4. Gather evidence of established clinical acceptance from guideline organizations and the FDA clearance record. 5. File the internal appeal with a prescriber letter and supporting documentation. 6. If denied internally, immediately file for external review — IROs regularly overturn experimental denials when clinical acceptance is well-documented.

## Documentation to Gather

• FDA 510(k) clearance: the clearance document for your specific device model from the FDA's 510(k) database, confirming it is FDA-cleared for treating sleep-disordered breathing.
• Guideline-organization support: a reference in the prescriber's letter to the relevant sleep-medicine guideline body's endorsement of PAP therapy as established standard of care for obstructive sleep apnea.
• Peer-reviewed literature reference: your prescriber can reference the existence of a robust clinical evidence base (without citing specific trial statistics) to support the established nature of the therapy.
• Diagnostic sleep study: confirming the established diagnosis and the appropriateness of PAP therapy for your severity and presentation.
• Prescriber medical-necessity letter: explicitly addressing each element of Humana's experimental-technology criteria and demonstrating that PAP therapy does not meet the definition of investigational for your indication.

## Criteria-Mapping Structure

Address each element of Humana's experimental/investigational definition:

| Humana Experimental-Technology Criterion | Rebuttal Evidence | |---|---| | FDA approval/clearance status | FDA 510(k) clearance number + date for specific device | | Accepted by recognized medical bodies | Prescriber letter citing applicable guideline organization | | Evidence base adequate for standard practice | Reference to established clinical literature (without specific statistics) | | Not under active investigation as primary endpoint | Device cleared and in routine clinical use for years |

Experimental denials for standard PAP therapy tend to resolve at either the internal appeal or external review stage. Submit your appeal promptly to preserve all timeline options.